- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Discontinuation of Beta-Blockers Risky in Post-MI Patients with Preserved LVEF and Hypertension: ABYSS trial

A new study published in the European Heart Journal showed that patients with myocardial infarction (MI) and preserved left ventricular ejection fraction (LVEF) who discontinue beta-blocker therapy experience notable increases in heart rate and blood pressure. This physiological response is associated with a heightened risk of adverse outcomes, especially in individuals with pre-existing hypertension.
In the coronary artery disease patients, β-blockers regulate blood pressure (BP) and heart rate (HR), which may be prognostic variables. However, the use of β-blockers to treat hypertension is becoming more and more controversial, and their antihypertensive effects are less important than their cardiovascular preventive properties.
And so, Niki Procopi and colleagues carried out this investigation to document the impact of stopping β-blocker treatment on blood pressure and heart rate in the AβYSS experiment, in which patients were randomly assigned to either stopping or continuing β-blocker therapy following a myocardial infarction.
The AβYSS study included 3698 participants with a median follow-up of 3.0 years. Changes in HR and BP from baseline to post-randomization are reported using a linear mixed repeated model. Additionally, the linear mixed repeated and adjusted Cox proportional hazards models were used to evaluate changes in HR and BP as well as the impact on the primary endpoint (death, MI, stroke, and hospitalization for cardiovascular reasons) in the pre-specified subgroups of patients with or without a history of hypertension.
Despite an increase in antihypertensive medications in the β-blocker interruption group, β-blocker interruption was linked to a significant increase in systolic blood pressure [+3.7 (2.6, 4.8) mmHg, P <.001], diastolic blood pressure [+3.3 (2.6, 4.0) mmHg, P <.001], and resting heart rate [+10 [9, 11) b.p.m., P <.001] at 6 months.
These changes continued throughout the follow-up period. Both hypertension patients (43% of the population) and non-hypertensive individuals experienced the effects. When compared to individuals without hypertension, those with hypertension had a greater risk of events (25.8% vs. 19.2%) (adjusted hazard ratio 1.18, 95% CI 1.01–1.36, P =.03).
When randomized to β-blocker interruption, patients with hypertension saw a notably significant rise in the main outcome (risk difference 5.02%, 0.72%–9.32%, P =.014). Overall, the AβYSS study results may be partially explained by this loss of BP and HR control after β-blocker cessation, which also exposes patients to potentially harmful long-term consequences on outcomes, particularly in those with a history of hypertension.
Source:
Procopi, N., Zeitouni, M., Kerneis, M., Cayla, G., Ferrari, E., Range, G., Puymirat, E., Delarche, N., Guedeney, P., Beygui, F., Desprets, L., Georges, J.-L., Bochaton, T., Schiele, F., Ducrocq, G., Hauguel-Moreau, M., Dumaine, R., Slama, M. S., Payot, L., … Montalescot, G. (2025). Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaf170
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751